Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-705 in Advanced HER2-expressing Solid Tumors
NCT05145179Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of SSGJ-705 in Solid tumors, sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 1 year and 2 more. Status: unknown.
02
Drugs
SSGJ-705
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT05145179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145179.